WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)”...
William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE...
WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress across its strategic acquisition initiatives...
WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding...
WARREN, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). Dear Shareholders, Since Tevogen’s 2024 public listing, we have remained...
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a securities purchase agreement for...
WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced continued progress within its artificial intelligence initiative,...
Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devices Target CRO operates...
WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) received written notice (the “Notification Letter”) from The Nasdaq...
WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that Mittul Mehta, Chief Information Officer and Head of...